Poster
137
A Retrospective Real-World Analysis Demonstrating the Value of Azstarys for Patients With Attention-Deficit Hyperactivity Disorder
Psych Congress 2022
Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the large-scale Komodo® Healthcare Map database.
Methods: Retrospective analyses were performed on data from open and closed insurance claims datasets spanning ~15 months (January 2021 to March 2022) to evaluate treatment patterns and use in ADHD patients. Patients were identified based on the diagnosis of ADHD (≥2 International Classification of Diseases-10 codes for ADHD) or through a fulfilled prescription for Azstarys. Patients with at least 90 days stability on Azstarys were analyzed for treatment patterns.
Results: Of the 3,568,005 patients with ADHD, 3367; 810,582; 1,045,162; and 943,825; were Azstarys, methylphenidate long-acting (MLA), amphetamine long-acting (ALA), and lisdexamfetamine users, respectively. In the Azstarys, MLA, ALA, and lisdexamfetamine, cohorts, the mean ages of patients were 19, 17, 27, and 25, years, respectively; 68%, 74%, 33%, and 42%, of patients were aged 18 years; and 60%, 64%, 51%, and 53%, were men. Patients treated for ADHD in this study were predominantly covered under a commercial or Medicaid insurance plan (47% and 29%, respectively). Patients using Azstarys were mostly from the southern region of the US as compared with the overall cohort treated for ADHD (70% vs 40%). Most Azstarys users (89%) received Azstarys without any supplementation with short-acting therapies over the 90-day period after Azstarys initiation.
Conclusion: Most patients transitioning to Azstarys do not require persistent use of concomitant short-acting ADHD medications over the 90-day period after Azstarys initiation.Short Description: The aim of this study was to quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the large-scale Komodo® Healthcare Map database. We show that most patients transitioning to Azstarys do not require persistent use of concomitant short-acting ADHD medications over the 90-day period after starting Azstarys.Name of Sponsoring Organization(s): Corium, Inc.
